BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

King Systems Slapped With FDA Warning Letter


10/30/2013 8:52:04 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

King Systems – owned by Ambu A/S – has received a Warning Letter from the U. S. Food and Drug Administration (FDA) relating to an inspection of the King Systems manufacturing site in Noblesville, USA. The Warning Letter references King Systems’ reply to the inspectional observations left by the FDA at the conclusion of the inspection.

The Warning Letter primarily addresses the timeline for validation of manufacturing processes for some legacy products. All new products and processes launched in the past 2.5 years have been validated, so this observation applies to retroactively validating the legacy processes. The Warning Letter is not expected to have consequences for products on the US market and little, if any, in other markets.

King Systems and Ambu take the request from FDA very seriously and has replied to FDA’s Warning Letter on October 21, 2013. This is part of the efforts to bring the aforementioned processes to a higher standard than ever before.

Contact

Lars Marcher, President & CEO, tel. +45 5136 2490, email: lm@ambu.com

Ambu A/S

Baltorpbakken 13

DK-2750 Ballerup

Tel. +45 7225 2000

CVR no.: 63 64 49 19

www.ambu.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES